VRCI Stock Overview
Develops of prognostic and diagnostic test for kidney transplant patients.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Verici Dx plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.077 |
52 Week High | UK£0.15 |
52 Week Low | UK£0.055 |
Beta | 1.53 |
1 Month Change | 6.90% |
3 Month Change | -24.39% |
1 Year Change | -32.61% |
3 Year Change | -89.60% |
5 Year Change | n/a |
Change since IPO | -78.77% |
Recent News & Updates
Shareholder Returns
VRCI | GB Biotechs | GB Market | |
---|---|---|---|
7D | -3.1% | 1.4% | -0.3% |
1Y | -32.6% | -21.2% | 5.5% |
Return vs Industry: VRCI underperformed the UK Biotechs industry which returned -19.4% over the past year.
Return vs Market: VRCI underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
VRCI volatility | |
---|---|
VRCI Average Weekly Movement | 5.8% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VRCI's share price has been volatile over the past 3 months.
Volatility Over Time: VRCI's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 14 | Sara Barrington | www.vericidx.com |
Verici Dx plc, develops of prognostic and diagnostic test for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.
Verici Dx plc Fundamentals Summary
VRCI fundamental statistics | |
---|---|
Market cap | UK£18.80m |
Earnings (TTM) | -UK£6.84m |
Revenue (TTM) | UK£793.17k |
23.7x
P/S Ratio-2.7x
P/E RatioIs VRCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VRCI income statement (TTM) | |
---|---|
Revenue | US$1.01m |
Cost of Revenue | US$0 |
Gross Profit | US$1.01m |
Other Expenses | US$9.75m |
Earnings | -US$8.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.036 |
Gross Margin | 100.00% |
Net Profit Margin | -862.19% |
Debt/Equity Ratio | 0% |
How did VRCI perform over the long term?
See historical performance and comparison